绵阳地区8家医疗机构冠心病患者用药现状调查分析
发布时间：2018-09-11 11:17
【摘要】：目的:了解冠心病住院患者用药现状,为相关决策提供参考。方法:通过医保系统提取绵阳地区8家医疗机构2014年1月-2016年12月冠心病患者病历资料,每家医疗机构抽取200份,采用Excel 2007、Access 2007、SPSS 19.0软件对患者性别、年龄、用药金额、药品品种、药品联用情况等进行统计分析。结果:共纳入1 600例患者,其中男性893例,女性707例,平均年龄(73.9±10.2)岁。药品费用占住院总费用的35.2%,冠心病治疗药物费用占药品费用的72.4%,辅助治疗用药中的中成药及4种改善循环的中药提取成分的化学药物费用占冠心病治疗药物费用的37.8%。主要治疗用药中,调脂药物使用率为80.8%,血管紧张素转化酶抑制剂(ACEI)和血管紧张素受体拮抗药(ARB)的使用率为46.9%。抗血小板药物联用质子泵抑制剂(PPIs)者占抗血小板药物使用者的54.9%;14例患者使用了短效的硝苯地平片;42例患者联用了氯吡格雷和奥美拉唑。结论:左卡尼汀等辅助用药费用占比较高;ACEI或ARB、调脂药物在冠心病患者中使用比例较低,选用短效钙通道阻滞药、双嘧达莫欠合理;PPIs使用指征控制不严;中成药滥用较为明显。
[Abstract]:Objective: to understand the current situation of drug use in patients with coronary heart disease (CHD) and to provide reference for relevant decision-making. Methods: the medical records of 8 medical institutions in Mianyang from January 2014 to December 2016 were collected. The patients' sex, age, amount of money and variety of drugs were analyzed by Excel 2007 access 2007 SPSS 19.0 software. Combined use of drugs and other statistical analysis. Results: a total of 1,600 patients were included, including 893 males and 707 females, with an average age of (73.9 卤10.2) years. The cost of medicine accounted for 35.2g of the total cost of hospitalization, the cost of coronary heart disease (CHD) accounted for 72.4% of the cost of medicine, the cost of Chinese patent medicine in adjuvant treatment and the cost of four kinds of chemical drugs which improved the circulation of traditional Chinese medicine components accounted for 37.8% of the cost of coronary heart disease treatment. The utilization rate of lipid-regulating drugs was 80.8, and that of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) was 46.9%. Anti-platelet drugs combined with proton pump inhibitor (PPIs) accounted for 54.9% of antiplatelet drug users in 14 patients who received short-acting nifedipine tablets in combination with clopidogrel and omeprazole. Conclusion: the cost of levacarnitine and other adjuvant drugs is low in patients with coronary heart disease. The use of short-acting calcium channel blocker and dipyridamole is not strictly controlled and the abuse of Chinese patent medicine is obvious.
【作者单位】： 西南医科大学药学院;绵阳市中心医院药学部;川北医学院药学系;
【基金】：四川省基层卫生事业发展研究中心重点项目(No.SWFZ16-Z-07)
【分类号】：R541.4
本文编号：2236540
[Abstract]:Objective: to understand the current situation of drug use in patients with coronary heart disease (CHD) and to provide reference for relevant decision-making. Methods: the medical records of 8 medical institutions in Mianyang from January 2014 to December 2016 were collected. The patients' sex, age, amount of money and variety of drugs were analyzed by Excel 2007 access 2007 SPSS 19.0 software. Combined use of drugs and other statistical analysis. Results: a total of 1,600 patients were included, including 893 males and 707 females, with an average age of (73.9 卤10.2) years. The cost of medicine accounted for 35.2g of the total cost of hospitalization, the cost of coronary heart disease (CHD) accounted for 72.4% of the cost of medicine, the cost of Chinese patent medicine in adjuvant treatment and the cost of four kinds of chemical drugs which improved the circulation of traditional Chinese medicine components accounted for 37.8% of the cost of coronary heart disease treatment. The utilization rate of lipid-regulating drugs was 80.8, and that of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) was 46.9%. Anti-platelet drugs combined with proton pump inhibitor (PPIs) accounted for 54.9% of antiplatelet drug users in 14 patients who received short-acting nifedipine tablets in combination with clopidogrel and omeprazole. Conclusion: the cost of levacarnitine and other adjuvant drugs is low in patients with coronary heart disease. The use of short-acting calcium channel blocker and dipyridamole is not strictly controlled and the abuse of Chinese patent medicine is obvious.
【作者单位】： 西南医科大学药学院;绵阳市中心医院药学部;川北医学院药学系;
【基金】：四川省基层卫生事业发展研究中心重点项目(No.SWFZ16-Z-07)
【分类号】：R541.4
【相似文献】
相关期刊论文 前4条
1 周长文;沈显群;贾骏;王懿钒;冷志宏;罗素新;;糖尿病合并冠心病老年患者氯吡格雷抵抗的危险因素分析[J];检验医学与临床;2014年10期
2 刘光全;付菊;;重庆市永川区老年冠心病合并糖尿病患者的高危因素分析及干预对策[J];检验医学与临床;2014年10期
3 胡艳;肖践明;;光学相干断层成像技术在冠心病临界病变中的应用[J];临床医学;2014年05期
4 温成泉,刘敏;阵发性室上性心动过速的特点及合理用药[J];实用心电学杂志;2003年02期
相关博士学位论文 前2条
1 何晨;临床因素和解剖因素联合应用对冠心病介入术后患者远期预后的预测价值[D];北京协和医学院;2017年
2 张丽娜;遗传变异与PCI术后冠心病患者临床预后的关系及多种遗传位点检测方法比较[D];华中科技大学;2015年
，本文编号：2236540
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2236540.html
最近更新
教材专著
